512 Results

OPTIMA study shows urticaria patients respond well to re- treatment with Xolair (omalizumab)-Novartis.

 Added 4 days ago

Novartis,announced new data showing almost 90% of chronic spontaneous urticaria (CSU) patients who responded well to initial Xolair (omalizumab) treatment...

Phase III CAFÉ study of Dupixent (dupilumab) in adults with moderate-to-severe atopic dermatitis where cyclosporine A isinadvisable.- Sanofi + Regeneron.

 Added 4 days ago

Sanofi and Regeneron Pharmaceuticals, Inc. announced positive results from the Phase III CAFÉ study of Dupixent (dupilumab) in adults with...

CHMP recommends approval of Tremfya (guselkumab) in the treatment of adults with moderate to severe plaque psoriasis.- Janssen-Cilag.

 Added 5 days ago

Janssen-Cilag International NV announced that the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending marketing...

Phase III data show Cosentyx (secukinumab) delivered high and long-lasting skin clearance in patients with moderate-to-severe plaque psoriasis at 5 years.- Novartis

 Added 6 days ago

Novartis announced first of its kind Phase III data showing Cosentyx (secukinumab) delivered high and long-lasting skin clearance in patients...

ADACCESS Phase III study of GP 2017 (biosimilar adalimumab) matches the originator medicine to treat plaque psoriasis.- Sandoz.

 Added 6 days ago

Sandoz,announces new data on its proposed biosimilar adalimumab. Data from a long-term study of patients continuously treated with the proposed...

SD 101 fails to meet endpoints in Phase III ESSENCE study to treat epidermolysis bullosa.- Amicus Therapeutics.

 Added 6 days ago

- Amicus Therapeutics, Inc. reported that top-line data from the randomized, double-blind, placebo-controlled Phase III clinical study (ESSENCE, SD-005) to...

IDP 118 (halobetasol propionate and tazarotene) filed with the FDA for the treatment of plaque psoriasis.- Ortho Dermatologics.

 Added 15 days ago

Ortho Dermatologics has submitted a New Drug Application (NDA) to the U.S. FDA for IDP 118 (halobetasol propionate and tazarotene)...

European Commission approves Imraldi, a biosimilar referencing Humira (adalimumab) to treat the originator drug indications- Biogen.

 Added 25 days ago

Samsung Bioepis Co., Ltd. announced the European Commission’s (EC) approval of Imraldi, a biosimilar referencing Humira (adalimumab), for the treatment...

Roche licenses lebrikizumab to Demira for atopic dermatitis and all other indications – except for interstitial lung diseases.

 Added 1 month ago

Dermira will obtain exclusive, worldwide rights to develop and commercialize lebrikizumab, a monoclonal antibody targeting interleukin 13 (IL-13), for atopic...

FDA Advisory Committee recommends tofacitinib for the treatment of adult patients with active psoriatic arthritis. - Pfizer

 Added 1 month ago

Pfizer Inc. announced that FDA Arthritis Advisory Committee (AAC) voted 10 to 1 to recommend approval of the proposed dose...

Load more